{"url_path":"/sec/artv/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-213242-index.html","accession_number":"0001193125-26-213242","cik":"0001817241","ticker":"ARTV","issuer_name":"Artiva Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-213242-index.html","primary_entity_key":"0001817241","primary_entity_name":"Artiva Biotherapeutics, Inc."},"word_count":359,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\nnumber\n\n \n\n \n\n \n\nIncorporated by Reference\n\n \n\nFiled\nHerewith\n\n \n\n \n\nDescription of document\n\n \n\nForm\n\n \n\nDate\n\n \n\nNumber\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  3.1\n\n \n\n[Amended and Restated Certificate of Incorporation.](https://www.sec.gov/Archives/edgar/data/1817241/000119312524182231/d863184dex31.htm)\n\n \n\n8-K\n\n \n\n7/22/2024\n\n \n\n3.1\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  3.2\n\n \n\n[Amended and Restated Bylaws.](https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948dex34.htm)\n\n \n\nS-1\n\n \n\n6/28/2024\n\n \n\n3.4\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  4.1\n\n \n\n[Form of Common Stock Certificate of the Registrant.](https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948dex41.htm)\n\n \n\nS-1/A\n\n \n\n7/15/2024\n\n \n\n4.1\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  4.2\n\n \n\n[Amended and Restated Investors’ Rights Agreement, dated February 22, 2021, by and among the Registrant and certain of its stockholders.](https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948dex42.htm)\n\n \n\nS-1\n\n \n\n6/28/2024\n\n \n\n4.2\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  10.1+\n\n \n\n[Consulting Agreement, dated January 1, 2026, by and between the Registrant and Neha Krishnamohan.](https://www.sec.gov/Archives/edgar/data/1817241/000119312525275872/artv-ex10_3.htm)\n\n \n\n10-Q\n\n \n\n11/12/2025\n\n \n\n10.3\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  10.2+\n\n \n\n[Employment Offer Letter, dated February 18, 2026, by and between the Registrant and Thad Huston.](https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-ex10_30.htm)\n\n \n\n10-K\n\n \n\n3/10/2026\n\n \n\n10.30\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 31.1\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](artv-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 31.2\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](artv-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 32.1*\n\n \n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](artv-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With embedded Linkbase Documents Document\n\n \n\n   \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\nX\n\n \n\n+ Indicates management contract or compensatory plan\n\n* This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n94\n\n \n\nSignatures\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nARTIVA BIOTHERAPEUTICS, INC.\n\n \n\n \n\nDate: May 8, 2026\n\n \n\nBy:\n\n/s/ Fred Aslan, M.D.\n\n \n\n \n\n \n\nFred Aslan, M.D.\n\n \n\n \n\n \n\nPresident and Chief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 8, 2026\n\n \n\nBy:\n\n/s/ Thad Huston\n\n \n\n \n\n \n\nThad Huston\n\n \n\n \n\n \n\nChief Financial Officer\n\n(Principal Financial Officer and Principal Accounting Officer)\n\n \n\n95"}